Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response

Vaccine

Volumn 17, Issue 22, 1999, Pages 2779-2785

  Dockrell, David H ^a   Poland, Gregory A ^b   Steckelberg, James M ^a   Wollan, Peter C ^a   Strickland, Scott R ^c   Pomeroy, Claire ^d  

^a MAYO CLINIC   (United States)

^b Mayo Vaccine Research Group   (United States)

^c Park Nicollet Institute   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL;

EID: 0033575488     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00089-4     Document Type: Article

References (26)

1. Keller D.W., Breiman R.F. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis. 21:1995;S77-S83.
2. Steinhart R., Reingold A.L., Taylor F., Anderson G., Wenger J.D. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA. 268:1992;3350-3352.
3. Selwyn P.A., Feingold A.R., Hartel D., et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS. 2:1988;267-272.
4. ACP Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for Adult Immunization. 1990;, Philadelphia.
5. Hecht F.M. H. influenzae vaccines in HIV. N Engl J Med. 326:1992;1569-1569.
6. Eskola J., Käyhty H., Takala A.K., et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus Influenzae type b disease. N Engl J Med. 323:1990;1381-1387.
7. Lieberman J.M., Greenberg D.P., Ward J.I. Prevention of bacterial meningitis: vaccines and chemoprophylaxis. Infect Dis Clin North Am. 4:1990;703-729.
8. Anderson P.W. Jr. New and improved vaccines against Hemophilus influenza type b. Woodrow G.C., Levine M.D. New generation vaccines. 1990;349-355 Marcel Dekker, New York.
9. Wenger J.D., Pierce R., Deaver K.A., et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet. 338:1991;395-398.
10. Gibb D., Spoülou V., Giacomelli A., et al. Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. Pediatr Infect Dis. 14:1995;129-135.
11. Kale K.L., King J.C. Jr., Farley J.J., Vink P.E., Cimino C.O., Paradiso P.R. The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants. Pediatr Infect Dis J. 14:1995;350-354.
12. Rutstein R.M., Rudy B.J., Cnaan A. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. Arch Pediatr Adolesc Med. 150:1996;838-841.
13. Steinhoff M.C., Auerbach B.S., Nelson K.E., et al. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med. 325:1991;1837-1842.
14. Granoff D.M., Holmes S.J. Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines. Vaccine. 9:(Suppl):1991;S30-S43.
15. Granoff D.M., Holmes S.J., Osterholm M.T., et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 168:1993;663-671.
16. Lucas A.H., Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J Immunol. 154:1995;4195-4202.
17. Käyhty H., Mäkelä O., Eskola J., Saarinen L., Seppälä I. Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18-24 months of age. J Infect Dis. 158:1988;973-982.
18. Shackelford P.G., Granoff D.M., Nelson S.J., Scott M.G., Smith D.S., Nahm M.H. Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide. J Immunol. 138:1987;587-592.
19. Dockrell D.H., Poland G.A., Mitchell P.S., et al. Effect of Haemophilus influenzae type b immunization on HIV viremia in HIV-seropositive adults. J Acquir Immune Defic Syndr Hum Retrovirol. 18:1998;512-514.
20. Farr R.S. A quantitative immunochemical measure of the primary interaction between I*BSA and antibody. J Infect Dis. 103:1958;239-262.
21. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 149:1984;1034-1034.
22. + T-cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
23. Kroon F.P., van Dissel J.T., de Jong J.C., van Furth R. Antibody response to influenza, tetanus, and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 8:1994;469-476.
24. Siber G.R., Santosham M., Reid G.R., et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med. 323:1990;1387-1392.
25. Yount W.J., Dorner M.M., Kunkel H.G., Kabat E.A. Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J Exp Med. 127:1968;633-645.
26. 1 is the predominant subclass of in vivo- and in vitro-produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B-cells. J Clin Immunol. 3:1983;65-69.